Hispanic arthritis affects an estimated 3.1 million adults across the United States, yet the variation in prevalence and impact among specific Hispanic subgroups has been largely invisible in the national data used to guide public health planning and clinical interventions. Arthritis is already the most common cause of disability among U.S. adults overall, affecting approximately 50 million people and driving significant activity limitation, work disability, reduced quality of life, and elevated healthcare costs. A CDC analysis of National Health Interview Survey data now provides the first nationally representative look at how Hispanic arthritis burden is distributed across subgroups, and the disparities are substantial.
How Hispanic Arthritis Prevalence Varies by Subgroup
The CDC analysis examined data from four survey years across more than 113,000 respondents and identified seven self identified Hispanic subgroups: Mexican, Mexican American, Central and South American, Puerto Rican, other and multiple Hispanic, Cuban and Cuban American, and Dominican and Dominican American.
Puerto Ricans reported the highest age adjusted prevalence of Hispanic arthritis at 21.8 percent, while Cubans and Cuban Americans reported the lowest at 11.7 percent. Across all subgroups, arthritis prevalence was highest among adults aged 65 and older, women, and individuals with obesity, defined as a body mass index of 30 or higher. The relationship between educational attainment and arthritis prevalence was inconsistent across subgroups, suggesting that socioeconomic factors alone do not account for the disparities observed.
The Burden of Hispanic Arthritis Beyond Diagnosis
The CDC analysis measured three arthritis attributable effects that go beyond prevalence to capture functional impact: arthritis attributable activity limitations, arthritis attributable work limitations, and severe joint pain defined as a self reported pain rating of seven or higher on a ten point scale.
Among Hispanics with arthritis, Puerto Ricans again reported the highest burden across multiple measures. Nearly half, 48.5 percent, reported arthritis attributable activity limitations, compared to 21.1 percent among Cubans and Cuban Americans. Puerto Ricans also reported the highest prevalence of severe joint pain at 44.1 percent. Approximately 1.4 million Hispanics reported arthritis attributable activity limitations overall, and an estimated 875,000 Hispanic adults aged 18 to 64 reported arthritis attributable work limitations, with Mexican Americans experiencing the highest rate at 41.6 percent.
These numbers reflect not just a health burden but an economic and social one. Work limitations driven by Hispanic arthritis affect earning capacity, household financial stability, and long term quality of life in ways that compound over time, particularly in communities that already face structural barriers to healthcare access.
Why Hispanic Arthritis Data Matters for Clinical Research
One of the most significant findings in this analysis is that while non Hispanic whites and non Hispanic blacks have a higher prevalence of doctor diagnosed arthritis compared to Hispanics overall, Hispanics and non Hispanic blacks experience a higher prevalence of arthritis attributable effects. This means that when Hispanics do have arthritis, the condition tends to impose a greater functional burden relative to other groups, a disparity that demands targeted clinical and public health attention.
For clinical researchers and trial sponsors, this data underscores the importance of including Hispanic subgroups in arthritis and rheumatology studies. Pooled Hispanic data obscures the meaningful differences between Puerto Rican, Mexican American, Cuban American, and other subpopulations, each of which may have distinct disease profiles, risk factors, and responses to intervention.
What This Means for Addressing Hispanic Arthritis Disparities
The CDC findings identify specific Hispanic subgroups with disproportionately high burdens of arthritis and arthritis attributable effects and call for interventions designed to improve quality of life in these communities. Effective interventions must be culturally and linguistically appropriate, accessible in the communities where these populations live, and informed by subgroup specific data rather than aggregated Hispanic averages.
Clinical research participation is one of the most direct pathways through which Hispanic communities can access emerging arthritis therapies and contribute to the evidence base that will shape treatment guidelines for their populations. Increasing minority representation in arthritis trials is not only a matter of equity but of scientific validity.
To learn more about FOMAT’s commitment to diversity in clinical research, visit FOMAT’s diversity page. To explore active studies, visit FOMAT’s patient studies page.
For the full source, see the original CDC report at CDC.gov.